Industry: Pharmaceuticals, Biotechnology
CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The Company owns three clinical-stage compounds based on its small molecule “molecular chaperone” co-induction technology. In September 2006, CytRx reported reaching the primary endpoints of safety and tolerability from a Phase IIa trial with its lead small molecule product candidate arimoclomol for the treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). Also in September 2006, CytRx announced receipt of ( www.cytrx.com )
CytRx Corporation
11726 San Vicente Blvd. Suite 650
Los Angeles, California 90049
USA
Tel: (310) 826-5648
Fax: (310) 826-6139